Richmond, Virginia 23298

  • Surgical Site Infection

Purpose:

This study is designed to collect data from 8,476 fracture patients during a pre-and post-intervention phases of two years length each. The intervention consists on the implementation of the AOT SSI Prevention Bundle. D


Study summary:

During the first phase of the study, 4,238 patients will be recruited and the baseline incidence of surgical site infection at each participating site will be determined. At the beginning of the third year, the bundle will be implemented and data on 4,238 additional patients will be collected. The incidence rate on surgical site infection before and after the intervention will be compared. We hypothesize that this intervention will reduce the infection rate within the first 3 months after surgery from 6% to 4.5% (5% to 3.75% in closed fractures and from 10% to 7.5% in open fractures).


Criteria:

Inclusion Criteria: - • Age > 18 years - Recent fracture (< 10 days) located in femur, tibia or humerus - Any type of open or closed fracture - Produced by high or low energy trauma - Primary fracture treatment with surgery and use of any of the following: - Intramedullary or extramedullary devices including cases in which a temporary external fixator is used - Joint replacement - Informed consent obtained (if required by local EC/IRB), i.e.: - Ability to understand the content of the patient information/ICF - Willingness and ability to participate in the clinical investigation according to the Clinical Investigation Plan (CIP) - Signed and dated EC/IRB approved written informed consent Exclusion Criteria: - Pathologic fracture secondary to tumors, infection or cysts - Patients with an underlying chronic, bone and joint infection or prior history of a bone and joint infection - Refracture and non-union - Peri-implant fractures - Patients with terminal illness - Pregnancy or women planning to conceive within the study period - Prisoner - Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study


NCT ID:

NCT03380273


Primary Contact:

Principal Investigator
Stephen Kates, MD
VCU Health

Severine Hurni, PhD
Phone: +41814142509
Email: severine.hurni@aofoundation.org


Backup Contact:

Hurni


Location Contact:

Richmond, Virginia 23298
United States

Stephen Kates, MD

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.